Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM5 | Q9NZQ8 | 9/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14417616 | 1.00 | TRPM5 (0.80) | TRPM5ALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL1223594 | 0.89 | TRPM5 (1.00) | TRPM5ALDH1A1KDM4ELMNAGAA | |
| SCHEMBL3862190 | 0.89 | TRPM5 (1.00) | TRPM5ALDH1A1KDM4ELMNAGAA | |
| SCHEMBL1223595 | 0.89 | TRPM5 (1.00) | TRPM5ALDH1A1KDM4ELMNAGAA | |
| SCHEMBL12881201 | 0.83 | TRPM5 (0.81) | TRPM5ALDH1A1KDM4ELMNAGAA | |
| SCHEMBL1225193 | 0.80 | TRPM5 (1.00) | TRPM5ALDH1A1KDM4ELMNAGAA | |
| SCHEMBL1225191 | 0.80 | TRPM5 (1.00) | TRPM5ALDH1A1KDM4ELMNAGAA | |
| SCHEMBL1225192 | 0.80 | TRPM5 (1.00) | TRPM5ALDH1A1KDM4ELMNAGAA | |
| SCHEMBL2782478 | 0.80 | TRPM5 (1.00) | TRPM5ALDH1A1KDM4ELMNAGAA | |
| SCHEMBL1225195 | 0.80 | TRPM5 (1.00) | TRPM5ALDH1A1KDM4ELMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951215-A4 | HYDRAZONE DERIVATIVES AND USES THEREOF | REDPOINT BIO CORP (US) | 2009-07-29 | — | — | EP | disclosed |
| US-7501425-B1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation | WARNER LAMBERT COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1951215-A2 | HYDRAZONE DERIVATIVES AND USES THEREOF | Redpoint Bio Corporation (US) | 2008-08-06 | — | — | EP | disclosed |
| EP-1080092-B1 | BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | LINQUAGEN CORP. | 2007-09-06 | — | — | US | disclosed |
| EP-1801112-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | disclosed |
| WO-2007056159-A2 | HYDRAZONE DERIVATIVES AND USES THEREOF | REDPOINT BIO CORPORATION (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | DOBRUSIN ELLEN MYRA (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | CCNI, CCNH, CCNA1 | TRPM5 2071/4885ALDH1A1 2575/4885HPGD 594/4885 |
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | TAS2R1, TAS2R5, TAS1R1 | TRPM5 49/4885ALDH1A1 72/4885HPGD 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.